Health Catalyst, Inc. filings document operating results, material-event reporting, and governance changes for a Nasdaq-listed healthcare data and analytics company. Recent Form 8-K disclosures include quarterly and annual financial results, preliminary unaudited financial updates, and press-release exhibits furnished under results-of-operations items.
The company’s filings also cover board appointments, executive transitions, compensatory arrangements, transition and separation agreements, executive severance-plan references, workforce-reduction disclosures, and related governance matters. These records provide formal disclosure around Health Catalyst’s management structure, financial condition, and material corporate events.
Health Catalyst, Inc. received an updated ownership report showing that Whetstone Capital Advisors, LLC and David Atterbury together beneficially own 3,750,377 shares of its common stock. This stake represents 5.3% of the company’s outstanding common shares as of the reporting date.
The filing states that the reporting persons share both voting and dispositive power over all of these shares and have no sole voting or dispositive authority. They also certify that the shares were not acquired for the purpose of changing or influencing control of Health Catalyst.
Health Catalyst, Inc. filed a Form 8-K to let investors know it has released an excerpt of its preliminary, unaudited estimated 2025 financial and operational results along with forward-looking commentary. The company notes these figures may change once year-end accounting and annual audit procedures are completed, so they should be viewed as estimates rather than final results. The information is provided in an “Excerpt” attached as Exhibit 99.1 and incorporated by reference. The company also specifies that this information is being furnished, not filed, which means it is not subject to certain liability provisions under the federal securities laws unless expressly incorporated into other filings.
Health Catalyst, Inc. (HCAT) reported Q3 2025 results. Revenue was $76.3 million, essentially flat year over year. Technology revenue rose to $52.1 million while Professional services declined to $24.3 million. Operating loss widened to $17.5 million and net loss was $22.2 million, or $0.32 per share.
Year to date, revenue reached $236.5 million with a net loss of $86.9 million, including a $28.8 million goodwill impairment. Gross costs held steady overall, but operating expenses increased, notably depreciation and amortization at $12.6 million in Q3. Interest and other expense was $4.7 million in Q3, driving a larger pre‑tax loss.
Liquidity contracted: cash and cash equivalents were $40.3 million as of September 30, 2025 versus $249.6 million at year‑end, reflecting $231.9 million of debt repayment and acquisition spending in the nine‑month cash flows. Total assets were $587.1 million and total liabilities $255.2 million. Shares outstanding were 70,730,884 as of November 5, 2025.
Health Catalyst (HCAT) furnished a press release announcing its financial results for the quarter ended September 30, 2025. The company attached the full release and a Q3 2025 earnings summary as Exhibit 99.1 and Exhibit 99.2, respectively. The materials are being furnished under Item 2.02 and are not deemed filed under the Exchange Act.
Albert Benjamin, President and COO of Health Catalyst, Inc. (HCAT), was granted 467,000 restricted stock units (RSUs) on 09/24/2025 under the companys 2019 Stock Option and Incentive Plan. Each RSU represents a contingent right to one share of common stock. After the grant, the filing reports 577,870 shares beneficially owned by the reporting person. The RSUs vest 33.33% on September 10, 2026, with the remaining 66.67% vesting in eight equal quarterly installments thereafter.
Albert Benjamin filed an initial Form 3 reporting his beneficial ownership in Health Catalyst, Inc. (HCAT). He directly holds 92,870 common shares and 18,000 restricted stock units (RSUs) granted under the 2019 Plan that vest beginning March 1, 2026. He also reports indirect holdings of 148,198 shares via the "Benjamin Albert Declaration of Trust" and 28,697 shares via the "Albert Family Trust." The filing is signed by an attorney-in-fact on 09/26/2025.
Health Catalyst, Inc. appointed Benjamin Albert as President and Chief Operating Officer effective September 16, 2025, following his leadership of the company’s Upfront Healthcare Services unit after its acquisition in January 2025. He brings prior experience as Upfront’s co‑founder and CEO, and will enter into Health Catalyst’s standard indemnification agreement and Executive Severance Plan.
Under an offer letter dated September 5, 2025, Mr. Albert will receive a $475,000 base salary, an annual bonus targeted at 75% of salary, 467,000 RSUs vesting over time, and 233,000 PRSUs tied over three years to total shareholder return versus the Russell 3000, adjusted EBITDA margin, and revenue growth rate. The filing also recaps the January 2025 Upfront merger, under which he received about $1,209,872 in cash, 269,765 Health Catalyst shares, and potential additional earn‑out consideration, plus earlier retention grants of 18,000 RSUs and 16,573 PRSUs. Current COO Dan LeSueur will cease serving as Chief Operating Officer and principal operating officer on September 15, 2025, which is stated not to be due to any disagreement with the company.
Benjamin Landry, General Counsel of Health Catalyst, Inc. (HCAT), reported a sale of 6,175 shares of the issuer's common stock on 09/05/2025 at a reported price of $3.353 per share. After the transaction, the reporting person beneficially owned 141,812 shares, held directly. The filing states the sale was executed pursuant to a written trading plan adopted on March 1, 2025 under Rule 10b5-1, providing pre-established instructions for the disposition. The Form 4 was signed on 09/09/2025.
Whetstone Capital Advisors, LLC and David Atterbury report beneficial ownership of 3,731,350 shares of Health Catalyst, Inc. common stock, representing 5.4% of the class. The filing shows the holders have shared voting and shared dispositive power over all 3,731,350 shares and no sole voting or dispositive power. The statement is submitted on a Schedule 13G related to the June 30, 2025 event and includes the filers' Kansas address and Health Catalyst's principal executive office in South Jordan, Utah. The filing includes a certification that the securities were not acquired to change or influence control of the issuer.
Julie Larson-Green, a director of Health Catalyst, Inc. (HCAT), had 4,588 restricted stock units (RSUs) vest on September 1, 2025. Each RSU converts to one share of common stock and the reported transaction shows no cash paid for the award. Following the vesting, Ms. Larson-Green is reported to beneficially own 115,839 shares directly. The Form 4 was signed on September 5, 2025, by an attorney-in-fact for the reporting person.